Why Sutro Biopharma Blasted 33% Higher on Friday

Why Sutro Biopharma Blasted 33% Higher on Friday
Eric Volkman, The Motley Fool

Sutro Biopharma (NASDAQ: STRO) was a rock star stock on Friday, with a mighty price increase on the back of some very good news released on Thursday. The company's STRO-002 cancer drug candidate showed impressive results in an early-phase clinical study involving patients with ovarian cancer. Updated data from the phase 1 clinical trial of STRO-002 showed that of the 31 evaluable participants, 23 reached disease control after 12 weeks, with 18 doing so after 16 weeks.